Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.34 |
| ▸ | HPGD | P15428 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CASP1 | P29466 | 3/20 | 0.33 |
| ▸ | CASP7 | P55210 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | CFTR | P13569 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437385 | 0.87 | STK17B (0.55) | STK17BSTK17AGAASYKKMT2A | |
| SCHEMBL2722836 | 0.87 | STK17B (0.55) | STK17BSTK17AGAASYKKMT2A | |
| SCHEMBL23868053 | 0.83 | STK17B (0.52) | STK17BSTK17AGAASYKKMT2A | |
| SCHEMBL2724784 | 0.82 | STK17B (0.34) | STK17BSTK17A | |
| SCHEMBL4187304 | 0.82 | STK17A (0.35) | STK17BSTK17AALDH1A1KDM4ELMNA | |
| SCHEMBL21952152 | 0.82 | STK17B (0.36) | STK17BSTK17A | |
| SCHEMBL17595889 | 0.82 | STK17B (0.31) | STK17BSTK17A | |
| SCHEMBL21967063 | 0.82 | SYK (0.30) | SYK | |
| SCHEMBL21967074 | 0.81 | STK17B (0.33) | STK17BSTK17A | |
| SCHEMBL21967069 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10927120-B2 | CDK inhibitors | GI Therapeutics, Inc. (NC) | 2021-02-23 | — | — | US | disclosed |
| US-20200277300-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040848-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2967050-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968290-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968291-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2831080-A1 | LACTAM KINASE INHIBITORS | Tavares, Francis Xavier (US) | 2015-02-04 | — | — | EP | disclosed |
| WO-2014144847-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144326-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013148748-A1 | LACTAM KINASE INHIBITORS | TAVARES FRANCIS XAVIER (US) | 2013-10-03 | — | — | WO | disclosed |
| EP-2632467-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885ALDH1A1 2981/4885 |
| US-20200277300-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885ALDH1A1 2981/4885 |
| US-10927120-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885ALDH1A1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.